Antiarrhythmic properties of ranolazine – from bench to bedside
Antiarrhythmic properties of ranolazine – from bench to bedside
复制标题
雷诺嗪的抗心律失常特性——从实验室到临床
DOI：
10.1517/13543784.2012.716826
复制
发表时间：
2012
影响因子：
6.1
通讯作者：
G. Andrikopoulos
中科院分区：
文献类型：
--
作者：
S. Tzeis;G. Andrikopoulos
引言：心律失常的药物治疗受到安全有效抗心律失常药物可用性减少的限制。涵盖的领域：雷诺嗪是目前用于治疗心绞痛的药物，其抑制心房和心室细胞中涉及动作电位几个相的跨膜离子电流。由于其作用机制，雷诺嗪已显示出在实验模型中验证的抗肿瘤特性。本文综述了雷诺嗪的抗癫痫作用机制、现有的临床数据和正在进行的相关临床试验。专家意见：雷诺嗪的抗缺血特性与其抗心律失常效力和最小促心律失常的组合提供了一个有希望的背景，可以扩展其在房颤和室性快速性心律失常管理中的治疗作用。来自充分把握度的随机临床试验的数据将决定雷诺嗪在不久的将来是否会打开新适应症的大门。
Introduction: Pharmacological management of cardiac arrhythmias is limited by the reduced availability of safe and effective antiarrhythmic agents. Areas covered: Ranolazine is an agent currently used for the treatment of angina, which inhibits transmembrane ionic currents involved in several phases of the action potential in both the atrial and the ventricular cells. Due to its mechanism of action, ranolazine has been shown to exhibit antiarrhythmic properties that have been validated in the experimental models. This article recapitulates the mechanism of antiarrhythmic action of ranolazine, the existing clinical data, and the ongoing relevant clinical trials. Expert opinion: The combination of the antiischemic properties of ranolazine with its antiarrhythmic potency and minimal proarrhythmia provides a promising background that could expand its therapeutic role in the management of atrial fibrillation and ventricular tachyarrhythmias. Data derived from adequately powered randomized clinical trials will determine whether the door to a new indication will open for ranolazine in the near future.
登录
查看更多内容
影响因子：
24
作者：
Burashnikov, Alexander;Sicouri, Serge;Di Diego, Jose M.;Belardinelli, Luiz;Antzelevitch, Charles
通讯作者：
Antzelevitch, Charles
影响因子：
5.5
作者：
Antzelevitch, Charles;Burashnikov, Alexander;Sicouri, Serge;Belardinelli, Luiz
通讯作者：
Belardinelli, Luiz
影响因子：
15.9
作者：
Wang, DW;Yazawa, K;Bennett, PB
通讯作者：
Bennett, PB
影响因子：
120.7
作者：
Go, AS;Hylek, EM;Singer, DE
通讯作者：
Singer, DE
影响因子：
158.5
作者：
Bardy, GH;Lee, KL;Ip, JH
通讯作者：
Ip, JH